BioSpace6h
Lilly Signs Back-to-Back Deals in MASH, Cancer
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
The Pharma Letter7h
OliX and Lilly ink licensing deal
South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.
ENDPOINTS NEWS23h
Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date
Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant ...